title: Value-engineered translation for regenerative medicine: meeting the needs of health systems.
abstract: Despite high expectations of economic returns, large investments in regenerative medicine technology have yet to materialize, partly due to a lack of proven business and investment models, regulatory hurdles, and a greater focus on cost-effectiveness for reimbursement decisions by payors. Adoption of new economic modeling methods will better link investment decisions to value-based criteria of health systems.
authors.affiliation: 1 School of Public Health, University of Alberta , Edmonton, Canada .
authors.forename: Tania
authors.initials: T
authors.lastname: Bubela
authors.forename: Christopher
authors.initials: C
authors.lastname: McCabe
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D007449:Investments; D044968:Regenerative Medicine / Q000191:economics*; D057905:Stem Cell Research / Q000191:economics*; D057170:Translational Research, Biomedical / Q000191:economics*